PROXY CORNER: Eli Lilly and Co.
Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Eli Lilly and Co.
Articles
Clot risk in Lilly lung-cancer drug raises FDA concerns
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday.
Resurgence of Eli Lilly is touching all corners of region
Central Indiana's economy is diverse, but Lilly is such a behemoth that its ups and downs reverberate statewide.
British court ruling backs patent protecting Lilly’s Alimta
Eli Lilly and Co. received some European legal backing for its top product, the lung cancer treatment Alimta, on Thursday when a British court upheld a patent protecting a vitamin regimen administered with the drug.
Lilly facing first trials over Cymbalta withdrawal symptoms
Eli Lilly and Co. has been ordered to face claims it misled consumers about “brain zaps” and other withdrawal side effects tied to its antidepressant Cymbalta in the first cases slated to be heard by juries.
Lilly drug regimen costing $9,200 a month scores zero in study
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
Lilly buoyed by string of positive results from drug trials
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Startup aims to upend diabetes care with matchstick-size implant
Intarcia Therapeutics Inc. is betting its matchstick-size pump could take market share from Eli Lilly and Co., AstraZeneca Plc and Novo Nordisk A/S.
Eli Lilly says it has ‘no intention’ to spin off animal health unit
Eli Lilly stock rose 5.4 percent per share on Tuesday, its biggest daily increase since March 2009, after Elanco President Jeffrey Simmons was asked if Lilly might one day shed the unit in an initial public offering.
Lilly to launch Lantus biosimilar in Europe in third quarter
Indianapolis-based Eli Lilly and Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.
Great Indy Innovations
Central Indiana has been the birthplace of groundbreaking innovation felt nationwide–even worldwide.
Indy’s Golden Age in 1920s shows way forward
In the 1920s, Indianapolis was one of the most innovative cities in the nation. But after “the dark tragedy of the roaring twenties,” Indianapolis lost its edginess for decades and only recently has begun to regain it.
Pace-setting firms share advice on diving into change, accelerating innovation
IBJ picked the brains of Indianapolis-area firms and organizations known for liquid thinking to discover how they open the spigot on innovation.
Lilly to market euro bonds as low rates lure U.S. firms
The drugmaker plans to sell 2.1 billion euros ($2.3 billion) of securities in three parts, according to a person familiar with the matter who asked not to be identified.
Lilly pledges $60M to German firm to form research partnership
In a bid to get into the white-hot market for drugs that use the body’s immune system, Eli Lilly and Co. will spend $60 million to form a research partnership with Germany-based BioNTech.
Former Lilly partner set to pay $2.3B to settle Actos cases
Takeda Pharmaceutical Co. executives have agreed to pay more than $2.3 billion to resolve lawsuits accusing the company of hiding its Actos diabetes medicine’s cancer risks, three people familiar with the accord said.
Princeton loses appeal in case sparked by Lilly drug loyalties
Four residents of the town of Princeton sued to revoke the university’s tax exemption, in part because it shares royalties with faculty, mostly from a patent that Indianapolis-based Eli Lilly and Co. turned into the cancer drug Alimta.
Lilly rethinks its philanthropy strategy
“Shared value” approach directs resources to help people in ways that could build the drugmaker’s business.
Alzheimer’s debate revived by new Mayo Clinic study
New research from the Mayo Clinic is bringing back a long-running debate over whether drug companies like Eli Lilly and Biogen are focusing on the right target in developing therapies to treat the disease.
Pay dips, but pension values soar for Lilly’s top execs
The top five executives at Eli Lilly and Co. took home 5 percent to 10 percent less in cash, stock and perks last year than the year before, according to a Monday securities filing.